View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
September 20, 2018updated 12 Jul 2022 1:12pm

Relmada doses 25% of subjects in Phase ll trial of dextromethadone

Relmada Therapeutics has completed dosing on 25% of the planned subjects in its Phase ll clinical trial of dextromethadone (REL-1017) to treat patients with major depressive disorder.

Relmada Therapeutics has completed dosing of 25% of the planned subjects in its Phase ll clinical trial of dextromethadone (REL-1017) to treat patients with major depressive disorder.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The dosing for the trial commenced in June last year and has not caused any of the patients treated with REL-1017 to experience serious adverse events or psychotomimetic adverse events.

REL-1017 has also continued to demonstrate an acceptable safety and tolerability profile, thereby validating the previously observed data from the Phase l single-ascending dose and several ascending-dose studies.

The trial is expected to be closed and publish top-line results in the first half of next year.

Relmada Therapeutics CMO and R&D head Dr Ottavio Vitolo said: “We are very pleased by the higher than expected enrolment rate that we have observed so far and by the emerging safety and tolerability data.

“Based on this positive initial enrolment, we continue to expect top-line data from this trial in the first half of 2019.”

“Based on this positive initial enrolment, we continue to expect top-line data from this trial in the first half of 2019.

“The recent New Drug Application submission for esketamine nasal spray, a potential first-in-class NMDA antagonist and rapidly acting antidepressant, is an important achievement for this new class of antidepressant drugs.”

The Phase ll trial is a multicentre, randomised, double-blind, placebo-controlled, three-arm study that aims to evaluate the safety, tolerability, and antidepressant effect of REL-1017 at two daily doses, including 25mg and 50mg.

It has been enrolling adult subjects with MDD who have had an inadequate response to one to three adequate courses of treatment during the current episode.

The trial is expected to enrol 60 subjects at around ten sites in the US.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena